- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06220214
Neoadjuvant terapi og kontrastforbedret mammografi for tidlig stadium av brystkreft
Kontrastforbedret digital mammografi for å forutsi patologisk fullstendig respons etter neoadjuvant kjemoterapi
The purpose of this study is to compare a special type of mammogram that uses a contrast agent called contrast-enhanced digital mammography with contrast-enhanced digital breast tomosynthesis (CEDM+CEDBT), with breast magnetic resonance imaging imaging (MRI) for predicting the effect of neoadjuvant chemotherapy on pathologic complete response rates. The device used to obtain CEDM+CEDBT images is called Siemens MAMMOMAT. This device produces two-dimensional (2D) images, as in a normal mammogram, but also collects additional images for digital breast tomosynthesis (DBT), which produces a three-dimensional (3D) image of the breast in the form of image slices. DBT allows the radiologist to "see through" the breast tissue for better detection and localization of breast cancer. By looking at both the CEDM images and the CEDBT images, a radiologist may be able to better detect residual breast cancer in a more cost-effective manner.
Participation may last up to 18 weeks.
Study procedures for this research are:
- Undergoing 1-2 mammograms during and/or after your chemotherapy, but before primary breast surgery.
- Before each mammogram, have a radiology technician inject a liquid contrast agent by inserting a needle into a vein. The chemotherapy port cannot be used to receive the contrast agent
- Let the research team record information from your medical record related to your condition and the treatment you receive.
- Give permission to collect leftover tissue from your diagnostic biopsy and breast surgery.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Tidlig fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Caterina Vacchi-Suzzi, PhD
- Telefonnummer: 631-216-2993
- E-post: caterina.vacchi-suzzi@stonybrookmedicine.edu
Studer Kontakt Backup
- Navn: Alison Stopeck, MD
- Telefonnummer: 631-444-7217
- E-post: alison.stopeck@stonybrookmedicine.edu
Studiesteder
-
-
New York
-
Stony Brook, New York, Forente stater, 11794
- Rekruttering
- Stony Brook Breast Center
-
Underetterforsker:
- Wei Zhao
-
Ta kontakt med:
- Caterina Vacchi-Suzzi, PhD
- Telefonnummer: 631-216-2993
- E-post: caterina.vacchi-suzzi@stonybrookmedicine.edu
-
Hovedetterforsker:
- Alison Stopeck, MD
-
Ta kontakt med:
- Hailiang Huang, PhD
- E-post: Hailiang.Huang@stonybrookmedicine.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosis with either type of invasive locally advanced breast cancer regardless of hormone receptor or Her2 status
- Plan to receive at least 4 cycles of neoadjuvant chemotherapy ahead of definitive surgery
Exclusion Criteria:
- Pregnancy
- Allergy/sensitivity to contrast agent
- Decreased kidney function
- Diabetes
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: CEDM + CEDBT
Participants undergo CEDM + CEDBT imaging after every 4-6 cycles of neoadjuvant chemotherapy prior to surgery (imaging may occur up to 2 times) |
Contrast Enhanced Digital Mammography Contrast-Enhanced Digital Breast Tomosynthesis Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Accuracy of (CEDM+CEDBT) to predict NAC treatment effects
Tidsramme: Immediately after definitive breast surgery, up to 24 weeks
|
The ability of CEDM + CEDBT to predict pathologic complete response to neoadjuvant chemotherapy, determined by histopathology evaluation of the resected breast |
Immediately after definitive breast surgery, up to 24 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Accuracy of (CEDM+CEDBT) to detect residual tumor compared with standard of care MRI
Tidsramme: Immediately before definitive breast surgery
|
Concordance between CEDM + CEDBT and standard of care MRI in quantifying residual tumor size |
Immediately before definitive breast surgery
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Alison Stopeck, MD, Stony Brook Cancer Center
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SBU-BC-NAC-CEDM
- IRB2023-00508 (Annen identifikator: Stony Brook IRB)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .